N-(3,4-dimethoxybenzyl)-6-(3,5-dimethylphenyl)-3-pyrrolidin-1-ylpyridazine-4-carboxamide | 1225016-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(3,4-dimethoxybenzyl)-6-(3,5-dimethylphenyl)-3-pyrrolidin-1-ylpyridazine-4-carboxamide
• 英文别名: N-[(3,4-dimethoxyphenyl)methyl]-6-(3,5-dimethylphenyl)-3-pyrrolidin-1-ylpyridazine-4-carboxamide
• CAS: 1225016-30-7
• 化学式: C₂₆H₃₀N₄O₃
• 分子量: 446.549
• InChiKey: BJZKTILRPJZBIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  76.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-chloro-N-(3,4-dimethoxybenzyl)-6-(3,5-dimethylphenyl)pyridazine-4-carboxamide 、 四氢吡咯 在 乙酸乙酯 、 hexanes 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 以to afford the product (1-4) as a white solid的产率得到N-(3,4-dimethoxybenzyl)-6-(3,5-dimethylphenyl)-3-pyrrolidin-1-ylpyridazine-4-carboxamide
  参考文献：
  名称：

  Pyridazine carboxamide orexin receptor antagonists

  摘要：

  本发明涉及吡啶嗪羧酰胺化合物，其是促进睡眠的荷尔蒙受体拮抗剂，可用于治疗或预防神经和精神障碍及疾病，其中促进睡眠的荷尔蒙受体参与其中。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗促进睡眠的荷尔蒙受体参与的疾病中的使用。

  公开号：

  US08703770B2

文献信息

• [EN] PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE À BASE DE PYRIDAZINE-CARBOXAMIDE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010051238A1

  公开（公告）日：2010-05-06

  The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及吡啶嗪羧酰胺化合物，这些化合物是促觉醒素受体拮抗剂，可用于治疗或预防涉及促觉醒素受体的神经学和精神疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及促觉醒素受体的疾病中的用途。
• Pyridazine Carboxamide Orexin Receptor Antagonists
  申请人：Coleman Paul J.

  公开号：US20120046289A1

  公开（公告）日：2012-02-23

  The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及吡啶嗪羧酰胺化合物，其为睡眠素受体的拮抗剂，并且在预防或治疗与睡眠素受体有关的神经和精神障碍和疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗与睡眠素受体有关的疾病方面的使用。
• PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2349267A1

  公开（公告）日：2011-08-03
• US8703770B2
  申请人：——

  公开号：US8703770B2

  公开（公告）日：2014-04-22
• Pyridazine carboxamide orexin receptor antagonists
  申请人：Coleman Paul J.

  公开号：US08703770B2

  公开（公告）日：2014-04-22

  The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及吡啶嗪羧酰胺化合物，其是促进睡眠的荷尔蒙受体拮抗剂，可用于治疗或预防神经和精神障碍及疾病，其中促进睡眠的荷尔蒙受体参与其中。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗促进睡眠的荷尔蒙受体参与的疾病中的使用。